Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) Director Kimberly Park sold 26,685 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $122.55, for a total value of $3,270,246.75. Following the sale, the director directly owned 30,000 shares in the company, valued at $3,676,500. This trade represents a 47.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Corcept Therapeutics Price Performance
CORT opened at $113.88 on Friday. Corcept Therapeutics Incorporated has a 1-year low of $28.66 and a 1-year high of $126.38. The stock has a market cap of $12.31 billion, a P/E ratio of 271.15 and a beta of 0.45. The stock’s 50 day simple moving average is $101.17 and its 200 day simple moving average is $67.37.
Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.34. The firm had revenue of $256.15 million during the quarter, compared to analysts’ expectations of $221.15 million. Corcept Therapeutics had a return on equity of 8.26% and a net margin of 6.52%.Corcept Therapeutics’s revenue was up 31.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.29 earnings per share. Research analysts expect that Corcept Therapeutics Incorporated will post 1.77 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Report on CORT
Hedge Funds Weigh In On Corcept Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the company. Torren Management LLC acquired a new stake in Corcept Therapeutics during the fourth quarter worth approximately $25,000. Advisory Services Network LLC purchased a new position in shares of Corcept Therapeutics during the 3rd quarter worth $25,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Corcept Therapeutics during the 2nd quarter worth $27,000. Atlas Capital Advisors Inc. acquired a new stake in shares of Corcept Therapeutics during the fourth quarter worth $31,000. Finally, State of Wyoming boosted its holdings in shares of Corcept Therapeutics by 29.5% during the first quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 186 shares during the last quarter. Hedge funds and other institutional investors own 93.61% of the company’s stock.
Corcept Therapeutics Company Profile
Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.
The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.
Read More
- Five stocks we like better than Corcept Therapeutics
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
